Company intelligence / Profile preview

Dynamic Precision

Ownership: Private
Development stage: Other

Overview

Adagene has advanced its lead program ADG106, a fully human agonistic monoclonal antibody targeting CD137, into Phase 1 trials in both the US and China. The company’s DPL platform enables rapid generation of mono-specific and bi-specific antibodies with unique epitope targeting. Early clinical data suggest promising safety and efficacy profiles in immuno-oncology settings. Strategic collaborations are ongoing with major pharma partners such as Exelixis for masked ADC development using SAFEbody technology.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyBispecific monoclonal antibodyAntibody-drug conjugateBiologic
Industry: Biotech

Partnerships

Exelixis (collaboration on masked ADCs using SAFEbody® technology)Additional undisclosed global partners leveraging DPL platform.

Beyond the preview

Go deeper on Dynamic Precision.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dynamic Precision.

Explore the full profile